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Abstract
The antitumor activity of pristine C60 fullerene aqueous solution (C60FAS) compared to 5-fluorouracil (5-FU) and
pyrrole derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF3-fenylamino)-1H-pyrrol-2.5-dione (MI-1) cytostatic drugs was investigated
and analyzed in detail using the model of colorectal cancer induced by 1.2-dimethylhydrazine (DMH) in rats. The
number, size, and location of the tumors were measured, and the pathology was examined. It was found that the
number of tumors and total lesion area decreased significantly under the action of C60FAS and MI-1. Because these
drugs have different mechanisms of action, their simultaneous administration can potentially increase the effectiveness
and significantly reduce the side effects of antitumor therapy.
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Background
C60 fullerene has been intensively investigated in the last
decades mainly because of their vast range of potential
applications in nanotechnology. The nearly spherical C60
molecule (diameter is 0.72 nm) can currently be rou-
tinely synthesized and is characterized by high chemical
stability and biological activity in vitro and in vivo [1–4].
C60 fullerenes are soluble in nonpolar organic solvents
[5] and can be transferred into the water by means of
special procedures [6–8]. These properties enable fuller-
ene to utilize in biological objects due to their ability to
easily penetrate the cell lipid membrane [9–12]. At low
(near-physiological) concentrations, C60 fullerenes dem-
onstrate no acute toxic effect in normal cells [13–17]. It
was also reported that C60 fullerene can be used in anti-
tumor therapy [18, 19], including the photodynamic ther-
apy for the treatment of oncological diseases [20–23] as
well as the targeted delivery of traditional drugs into
cancer cells [24, 25].
Colon cancer (colorectal cancer) is one of the most
common diagnoses in the world, which corresponds to
approximately 1.4 million patients in 2012, and this
number is foreseen to increase by almost half in 2035
[26, 27]. The 5-year relative survival rate for patients
with colorectal cancer is in between 12 and 90% and
strongly depends on the time passed till diagnosis, the
stage of the disease, and the conducted treatment [28].
Colorectal carcinogenesis is a heterogeneous and com-
plex multistage process, which involves violations of a
homeostatic control of proliferation, differentiation, and
apoptosis of intestine epithelial cells. The causes of these
disorders are genetic mutations of transforming oncogenes
and deletions or mutations of DNA repair genes and
tumor suppressor genes. In addition, indirectly acting fac-
tors, such as diet and environmental factors, may contrib-
ute to the development of cancer via the modulation of
signaling pathways of intestinal epithelial cells. Multiple
mutations over many years are required for the occurrence
of abnormal growth that leads to colon cancer [29, 30].
Artificially induced (by a specific carcinogen) tumors
in laboratory animals provide an opportunity to investi-
gate various aspects of carcinogenesis that cannot be ef-
fectively studied in the human body directly [31–33].
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Therefore, a significant number of the experimental
models of tumorigenesis in various organs were devel-
oped. The dimethylhydrazine model is an effective tool
to study the features of intestinal carcinogenesis under
the action of therapeutic agents. Morphological changes
in rat intestine caused by the 1.2-dimethylhydrazine
(DMH) are similar to those that occur during the colon
cancer development in human tissues [32, 34].
The aim of this work was to study and analyze the
antitumor activity of pristine C60 fullerene aqueous so-
lution (C60FAS) compared with the effect of pyrrole de-
rivative 1-(4-Cl-benzyl)-3-Cl-4-(CF3-fenylamino)-1H-pyrrol-
2.5-dione (MI-1) and the most commonly used 5-
fluorouracil (5-FU) drug on the DMH-induced colon
cancer model in rats.
Methods
A highly stable reproducible C60FAS in concentration
0.15 mg/ml was prepared according to the protocol [7, 8].
Small-angle X-ray scattering (SAXS) experiments were
carried out on instrument with high-intensity microfocus
rotating Cu anode X-ray generator in the laboratory
for advanced studies of membrane proteins (Moscow
Institute of Physics and Technology, Dolgoprudniy,
Russia), using a standard transmission configuration.
An X-ray wavelength of λ = 1.54 Å was used, resulting
a momentum transfer Q in the range of 0.007–0.2 Å−1,
where Q = (4π/λ) × sin(θ/2) and θ is the scattering angle.
The samples studied were placed in borosilicate capillaries
of 1.5-mm diameter and 0.01-mm wall thickness (W.
Muller, Berlin, Germany). Water was used as a buffer
sample. Center of beam line and conversation channel
to value of module q-vector was done using silver behenate.
Pyrrole derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF3-fenylamino)-
1H-pyrrole-2.5-dione (MI-1) was synthesized by the
ChemBioCenter in Taras Shevchenko National University
of Kyiv [35, 36].
2.4-Dihydroxy-5-fluoropyrimidine (5-FU; “Darnitsa,”
Ukraine) was used in experiments.
The study was conducted on 60 white male rats of the
“Wistar” line weighing 180–200 g. The animals were kept
under standard conditions in the vivarium of the ESC
“Institute of Biology and Medicine,” Taras Shevchenko
National University of Kyiv. Animals had free access to
food and water. All experiments were conducted in ac-
cordance with the international principles of the European
Convention for the protection of vertebrate animals under
a control of the Bio-Ethics Committee of the abovemen-
tioned institution.
Colorectal cancer was induced by DMH (Sigma-
Aldrich, USA), which was administered weekly for
20 weeks at a dose of 20 mg/kg (the dose and duration of
administration are sufficient for the induction and sub-
sequent development of colorectal cancer in rats) [37].
Starting from the 21 weeks of the experiment, the ani-
mals were divided into four groups: I—control (animals
were given subcutaneous injections of saline weekly);
II—animals were treated by subcutaneous injections of
C60FAS at a dose of 2.0 mg/kg weekly; III—animals
were treated by subcutaneous injections of 5-FU at a
dose of 45 mg/kg weekly; IV—animals were given MI-1
intragastric at a dose of 2.7 mg/kg daily. After 27 weeks,
the animals were submitted to euthanasia with CO2.
Immediately after euthanasia, the intestine was removed
(from the cecum to the anus) and was opened with scissors
in the antimesenteric border and stretched in Styrofoam
plates for cleaning with 0.9% NaCl. The number, location,
and area of the neoformations were determined by special
procedures [38]. The tumors were excised and fixed in
10% neutral buffered formalin and then subjected to stand-
ard histological processing and staining with hematoxylin
and eosin. Slides were analyzed using a light microscope
Olympus BX-41 (Germany). The obtained results were
treated by conventional methods of statistics using
StatPlus2009 software.
Modeling of the coordination complex of C60 fullerene
with Fe ion was accomplished using the C60(OH)24 full-
erenol model of the C60 molecule. The initial structure
of C60(OH)24Fe(H2O)3 was built by creating its geometry
similar to the well-established geometry of the Fe(H2O)3
octahedral cluster in water [39]. The spatial structure of
C60(OH)24Fe(H2O)3 was preliminary optimized by means
of the MM+ molecular mechanics method in HyperChem
8.0. The final optimization was made by means of the
PM6 method in Gaussian09W.
Results and Discussion
Since the C60 fullerene particles size directly correlates
with their biodistribution and toxicity [3, 15, 16], SAXS
study of C60FAS was performed.
The experimental SAXS curve of C60FAS is shown in
Fig. 1. The absence of specific peculiarities on the curve
Fig. 1 Experimental SAXS curve for C60FAS with concentration
0.15 mg/ml. The solid line illustrates the calculated scattering
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suggests that the particles are polydisperse in size. It is
in a good agreement with probe microscopy data [40, 41].
At sufficiently small q values (qRg < 1), the scattered inten-
sity can be described by the Guinier approximation
I qð Þ ¼ I 0ð Þ exp − qRg
 2=3n o
with two parameters, which are the forward scattered in-
tensity, I(0), and the apparent radius of gyration, Rg. The
found gyration radius of clusters, Rg, is about 20 nm. For
spherical homogeneous approximation in the case of
C60FAS [6, 40, 42, 43], the C60 fullerene nanoparticle
size can be estimated as 2 × (5/3)1/2 × Rg, which gives the
effective diameter about 52 nm.
All experimental rats had tumors in the colon. The
vast majority of tumors were detected in the descending
colon, which is typical for this model of carcinogenesis
[32]. Neoplasms had different sizes and shapes (flat,
protruding, raised, recessed, granular, and agranular) with
exophytic and entophytic types of growth. From the histo-
logical studies, the adenoma and adenocarcinoma were
found (data not shown). Rats treated by C60FAS mainly
had adenoma.
Table 1 shows the average size of tumors, the average
number of tumors, and the total area of lesions of differ-
ent parts of the colon under the action of DMH.
Introduction of C60FAS caused the reduction of the
number of tumors in the cecum by 57% and the total le-
sion area by 65% (Table 1). Under the 5-FU action, only
the downward trend of these rates was observed.
In the colon, the number of tumors has reduced by
28% and the total lesions area by 40% under the C60FAS
action; it was close to the 5-FU effects (Table 1). A ten-
dency to the reduction of the average area of tumors
was also observed.
In the rectum, the number of tumors had demon-
strated a tendency to reduction and the total lesions area
had decreased by 33% under the C60FAS action (Table 1).
Under the action of traditional anticancer drug, 5-FU,
only a tendency to decrease the average tumor area and
the total lesion area was noted.
In total, in the colon, C60FAS reduced the number of
tumors by 31% and the total lesion area by 42% (Table 1).
Nearly the same quantitative changes had also occurred
under the action of 5-FU, viz. the tumor area decreased
by 28% and the total lesion area by 43%.
The antitumor effect of MI-1 was similar to C60FAS
and 5-FU: the average number of tumors, tumor size,
and total lesions area were reduced (Table 1). Note that
MI-1 is characterized by low toxicity in the gastrointes-
tinal tract and hematopoietic organs [44, 45].
Thus, therapeutic administration of C60FAS, 5-FU, and
MI-1 leads to a reduction of the number of DMH-
induced tumors and colon lesion area in rats. MI-1 and
5-FU drugs (the latter is related to antimetabolites and
pyrimidine antagonists, whose antitumor effect manifests
itself as a result of 5-fluorouracil converted to fluorodeox-
yuridine monophosphate, fluorodeoxyuridine triphosphate,
and fluorouridine triphosphate [46]) violate DNA synthesis
and, as a consequence, inhibit cell division. The mechan-
ism of C60 fullerene action is different and can be related
to its antioxidant effect [47, 48] that causes the epigenetic
changes in tumor cells, which inhibit their further growth.
As a result of the DMH metabolism in the liver, the forma-
tion of electrophilic diazonium ions occurs [32], which
causes an oxidative stress. C60 fullerene, being a powerful
antioxidant, is able to prevent the progression of tumors at
an early stage. Based on the fact that MI-1 and C60 ful-
lerene have different mechanisms of action, the observed
effectiveness of their combined action on the colorectal
Table 1 The effectiveness of 5-FU, MI-1, and C60FAS at DMH-induced colon cancer (M ±m; n = 15)
Parts of the large
intestine
Experimental group
DMH DMH + 5-FU DMH + C60FAS DMH +MI-1
Average number of tumors, per rat Cecum 2.8 ± 0.4 1.8 ± 0.3 1.2 ± 0.1* 1.3 ± 0.2*
Colon 11.5 ± 1.0 9.0 ± 0.4 8.3 ± 0.2* 8.6 ± 0.7*
Rectum 2.6 ± 0.3 2.8 ± 0.4 2.0 ± 0.3 1.9 ± 0.2
All parts 16.8 ± 1.0 13.5 ± 0.7 11.5 ± 0.3* 11.8 ± 0.8*
Average area of tumors, mm2 Cecum 9.6 ± 1.8 6.4 ± 1.0 9.4 ± 1.7 5.0 ± 1.0*
Colon 15.0 ± 1.6 9.0 ± 0.5 11.2 ± 0.7 11.6 ± 0.5
Rectum 22.0 ± 2.1 18.6 ± 2.1 18.4 ± 1.1 16.1 ± 2.0
All parts 14.5 ± 1.1 10.3 ± 0.5* 12.1 ± 0.6 11.4 ± 0.5*
Total area of tumors, per rat, mm2 Cecum 30.5 ± 8.1 11.1 ± 2.0 10.5 ± 1.6* 6.3 ± 1.2*
Colon 158.9 ± 11.7 79.7 ± 1.8* 95.0 ± 7.8* 100.9 ± 10.3*
Rectum 51.9 ± 5.1 45.8 ± 5.5 34.6 ± 3.3* 29.2 ± 4.7*
All parts 241.3 ± 16.4 136.6 ± 6.1* 140.0 ± 10.3* 136.4 ± 12.9*
*p < 0.05 relative to control
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carcinogenesis model can therefore be explained, at least
in part. Hence, the simultaneous administration of MI-1
and C60 fullerene can potentially increase the effectiveness
of anticancer therapy and reduce side effects, reported re-
cently for other C60 fullerene-drug combinations [49, 50].
Let us further discuss the possible mechanism by which
the antioxidant effect of C60FAS may operate in the sys-
tem investigated in the present work.
It is currently considered that the water-soluble C60
fullerene derivative, C60(OH)24 fullerenol, exerts its pro-
tective role against doxorubicin-induced toxicity due to
the removal of free iron, forming a stable “fullerenol-iron”
complex [51]. Because the cancer cells grow rapidly in re-
sponse to iron, the formation of colorectal cancer can
therefore be inhibited by the removal of free iron in the
form of “fullerenol-iron” nanoparticles. Let us further
consider the possibility of formation of stable complex
between pristine C60 fullerene used in the present work
(not containing the –OH groups), and the iron ions,
which cannot be expected from the very beginning.
It has long been established that the dissolution of
pristine C60 fullerene in water is due to the formation of
solvation shell around the C60 molecule tightly attached
to it [5, 6, 43, 52, 53]. However, recent data have evidenced
that the molecular dissolution of the C60 fullerene in
water, at least in part, is promoted by the attachment of a
certain number of OH groups to the C60 fullerene surface,
i.e., the pristine C60 fullerene in water becomes partially
hydroxylated [7, 54]. The number of the –OH groups at-
tached to the surface is still unknown, but the literature
data suggest that the C60 molecule may incorporate 2 to
44 hydroxyls freely migrating around the C60 fullerene
surface [55]. On the other hand, the coordination number
of the transition metal ions, including the iron ions such
as Fe+2 and Fe+3, typically equals to 6. In water, the Fe ions
are coordinated by six water molecules forming regular
octahedral. Taking this into account, it can be assumed
that the “C60 fullerene-iron” complex may be formed by
the coordination of three –OH groups on the surface of
C60 fullerene and three water molecules from the bulk so-
lution. The corresponding energy-minimized structure of
the proposed complex is given in Fig. 2a. The stability of
such structure is verified by the fact that the resultant
geometry of the coordinated cluster well matches the
geometry of the stable Fe octahedral in water (Fig. 2b), i.e.,
the distance between Fe ion and water oxygen in hydrated
ions is close to the same distance in C60 fullerene-iron
octahedral (≈2 Å). We consider that such complexation of
Fe to water-soluble pristine C60 fullerene may explain the
antioxi-dant effect of C60FAS synergistically/additively
operat-ing together with doxorubicin [49] or MI-1 in
suppres-sion the tumor growth.
Conclusions
It was found that the administration of pristine C60 fuller-
ene aqueous solution (C60FAS), 5-fluorouracil (5-FU), and
pirrole derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF3-fenylamino)-
1H-pyrrol-2.5-dione (MI-1) reduces the number of 1.2-
dimethylhydrazine-induced tumors and colon lesion
area in rats. The antitumor effects of C60FAS and MI-1
demonstrated no significant difference but additively
operate in tumor suppression on their simultaneous use.
These results point out the possibility of the practical ap-
plication of C60FAS and MI-1 in the combination therapy
of colorectal cancer.
Abbreviations
5-FU: 5-Fluorouracil; DMH: 1,2-Dimethylhydrazine; MI-1: Pyrrole derivative
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Fig. 2 Hydrated iron ion (Fe ion is located in the center of octahedral. Water molecules are located in heights (a); the calculated structure of the
“C60 fullerene-iron” complex (b)
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